FRES Stock Overview
A biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Fresh2 Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.85 |
| 52 Week High | US$9.00 |
| 52 Week Low | US$0.73 |
| Beta | 1.25 |
| 1 Month Change | -25.68% |
| 3 Month Change | -42.18% |
| 1 Year Change | -88.19% |
| 3 Year Change | -99.60% |
| 5 Year Change | n/a |
| Change since IPO | -99.96% |
Recent News & Updates
Recent updates
AnPac Bio announces plan to implement ADS ratio change
Oct 18AnPac Bio-Medical Science announces management changes
Oct 03AnPac Bio-Medical Science signed equity investment totaling $3.67M with new investor Group
Sep 27AnPac Bio appoints Yuyang Cui as co-chief executive officer
Aug 05AnPac Bio stock soars 15% after securing first disease treatment patent in U.S.
Jun 18AnPac Bio wins new US patent for multi-cancer detection
Feb 01AnPac Bio (ANPC) skyrockets 136% on advancement in detecting pre-cancer diseases
Dec 14Industry Analysts Just Upgraded Their AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) Revenue Forecasts By 55%
Dec 11
AnPac Bio-Medical rallies on Q3 record test volume; FY20 revenue estimated at +100%
Nov 25AnPac Bio's Chinese company secures COVID-19 nucleic acid test certification; shares +33%
Nov 02Shareholder Returns
| FRES | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -26.1% | 2.1% | 2.8% |
| 1Y | -88.2% | -3.8% | 24.5% |
Return vs Industry: FRES underperformed the US Biotechs industry which returned -1.9% over the past year.
Return vs Market: FRES underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| FRES volatility | |
|---|---|
| FRES Average Weekly Movement | 21.2% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: FRES's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: FRES's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 75 | Haohan Xu | fresh2.co |
Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People’s Republic of China. It also offers physical checkup packages, as well as technology services comprising market research, designing, coding, developing, testing, etc. In addition, the company sells genetic testing kits and skin-care products; and owns core technology platforms, as well as engages in technology development and product distribution. Further, it operates an e-commerce platform that connects food suppliers and supermarket operators and restaurant owners.
Fresh2 Group Limited Fundamentals Summary
| FRES fundamental statistics | |
|---|---|
| Market cap | US$1.89m |
| Earnings (TTM) | -US$18.70m |
| Revenue (TTM) | US$2.33m |
0.8x
P/S Ratio-0.1x
P/E RatioIs FRES overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FRES income statement (TTM) | |
|---|---|
| Revenue | CN¥16.98m |
| Cost of Revenue | CN¥7.75m |
| Gross Profit | CN¥9.23m |
| Other Expenses | CN¥145.65m |
| Earnings | -CN¥136.42m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -61.38 |
| Gross Margin | 54.38% |
| Net Profit Margin | -803.40% |
| Debt/Equity Ratio | 0.01% |
How did FRES perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 23:51 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fresh2 Group Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Theodore O'Neill | Litchfield Hills Research, LLC |